- Home
- PMVP
as 10-29-2025 4:00pm EST
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 82.7M | IPO Year: | 2020 |
| Target Price: | $5.00 | AVG Volume (30 days): | 757.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.81 - $1.84 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of PMV Pharmaceuticals Inc. (PMVP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | PMVP | 10% Owner | Oct 23 '25 | Sell | $1.52 | 1,000,000 | $1,520,000.00 | 4,975,291 | |
| ORBIMED ADVISORS LLC | PMVP | 10% Owner | Sep 10 '25 | Sell | $1.80 | 500,000 | $900,000.00 | 4,975,291 |
Latest PMV Pharmaceuticals Inc. News
PMVP Breaking Stock News: Dive into PMVP Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
PMV Pharmaceuticals Says Updated Rezatapopt Data Show 46% Response Rate in Ovarian Cancer
GlobeNewswire
5 days ago
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
GlobeNewswire
16 days ago
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
GlobeNewswire
5 months ago
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
Simply Wall St.
5 months ago
We're Keeping An Eye On PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Rate
GlobeNewswire
6 months ago
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights
Zacks
8 months ago
Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing
GlobeNewswire
8 months ago
PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights
Compare PMVP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PMVP PMV Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.